De Deyn P P, Marescau B, D'Hooge R, Possemiers I, Nagler J, Mahler C
Laboratory of Neurochemistry and Behavior, A.Z. Middelheim, Born-Bunge Foundation, University of Antwerp, Belgium.
Neurochem Int. 1995 Sep;27(3):227-37. doi: 10.1016/0197-0186(95)00041-6.
Guanidino compounds have been suggested to contribute to the complex neurological complications associated with uremia. Several of them have previously been reported to accumulate in physiological fluids of renal insufficient subjects. We report on guanidino compound levels in 28 brain regions in control and uremic brains. In all brain regions studied, in controls as well as in uremic patients, concentrations of alpha-keto-delta-guanidinovaleric acid, alpha-N-acetylarginine and beta-guanidinopropionic acid remained below detection limits. Creatine, guanidinoacetic acid, argininic acid, gamma-guanidinobutyric acid, arginine and homoarginine were not increased in uremic patients. Argininic acid and homoarginine were detectable in some brain regions only. Creatine concentrations varied from 2500 +/- 2100 nmol/g tissue in hypophysis to 10500 +/- 1200 nmol/g tissue in cerebellar cortex. Even more pronounced regional differences were found for gamma-guanidinobutyric acid with the lowest concentration in the caudate nucleus (0.6 +/- 0.3 nmol/g tissue) and highest in substantia nigra, pallidum and cerebellar dentate nucleus (8.3 +/- 2.8 nmol/g tissue). The guanidinosuccinic acid levels were below detection limit in controls in the majority of brain regions. Taking into account the detection limit of guanidinosuccinic acid for a certain amount of tissue applied to the analytical system, important increases (approx. up to > 100 fold) were observed in all brain regions of uremic patients. Accumulation of guanidinosuccinic acid increased with increasing degree of renal failure with levels up to 65 nmol/g tissue in the hypophysis. Creatinine concentrations were also found to be increased in uremic brain regions but increases seemed to be less strictly related to serum urea levels. Guanidine and methylguanidine were found only occasionally in brain regions of controls while respectively 100- and 30-fold increases were found in brain regions of uremic subjects. Levels of guanidinosuccinic acid and creatinine in uremic brain were comparable to those previously observed in brain of experimental animals displaying convulsions following intraperitoneal injection of the respective compounds. Our findings further establish guanidino compounds as probable uremic toxins contributing to the neurological complications in uremia.
胍类化合物被认为与尿毒症相关的复杂神经并发症有关。此前有报道称,其中几种化合物会在肾功能不全患者的生理体液中蓄积。我们报告了对照脑和尿毒症脑28个脑区中的胍类化合物水平。在所有研究的脑区中,无论是对照组还是尿毒症患者,α-酮-δ-胍基戊酸、α-N-乙酰精氨酸和β-胍基丙酸的浓度均低于检测限。尿毒症患者体内的肌酸、胍基乙酸、精氨酸酸、γ-胍基丁酸、精氨酸和高精氨酸并未增加。仅在部分脑区可检测到精氨酸酸和高精氨酸。肌酸浓度在垂体中为2500±2100 nmol/g组织,在小脑皮质中为10500±1200 nmol/g组织。γ-胍基丁酸的区域差异更为明显,尾状核中的浓度最低(0.6±0.3 nmol/g组织),黑质、苍白球和小脑齿状核中的浓度最高(8.3±2.8 nmol/g组织)。在大多数脑区的对照组中,胍基琥珀酸水平低于检测限。考虑到应用于分析系统的一定量组织中胍基琥珀酸的检测限,在尿毒症患者的所有脑区均观察到显著升高(约高达100倍以上)。胍基琥珀酸的蓄积随着肾衰竭程度的增加而增加,垂体中的水平高达65 nmol/g组织。在尿毒症脑区也发现肌酐浓度升高,但升高似乎与血清尿素水平的关系不太紧密。在对照组的脑区中仅偶尔发现胍和甲基胍,而在尿毒症患者的脑区中分别发现升高了100倍和30倍。尿毒症脑中胍基琥珀酸和肌酐水平与先前在腹腔注射相应化合物后出现惊厥的实验动物脑中观察到的水平相当。我们的研究结果进一步证实胍类化合物可能是导致尿毒症神经并发症的尿毒症毒素。